CLL Highlights from ASH 2024

William G. Wierda, MD, PhD discusses current questions and state of the art treatement of chronic lymphocytic leukemia at the 2024 ASH Annual Meeting.

Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control

Prof. Francesco Passamonti discusses the state of the art treatment in myelofibrosis Care at the 2024 ASH Annual Meeting.

State of the Art Treatment in Lymphoma

Catherine S. Diefenbach, MD  discusses the state of the art treatment in lymphoma care at the 2024 ASH Annual Meeting.

State of the Art Treatment in Adult ALL

Anand A. Patel, MD discusses the state of the art treatment in adult acute lymphoblastic leukemia at the 2024 ASH Annual Meeting.

Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-base Platforms

Matthew S. Davids, MD, MMSc discusses the state of the art treatment in chronic lymphocytic leukemia at the 2024 ASH Annual Meeting.

Bridging Gaps in Multiple Myeloma Care: A Community Oncologist's Guide to Navigating the Evolving Treatment Landscape

Rahul Banerjee, MD, FACP discusses the state of the art treatment in Multiple Myeloma Care at the 2024 ASH Annual Meeting.

24-hour Urine Testing does not Add Value to Multiple Myeloma Response Assessments

Rahul Banerjee, MD, FACP comments on the role of 24-hour urine testing in assessing multiple myeloma treatment responses at the 2024 ASH Annual Meeting.

Do GLP-1s Lower VTE Risk in People With Type 2 Diabetes?

Cho Han Chiang, MD, MMSc presented an analysis at the 2024 ASH Annual Meeting, that shows GLP-1 receptor agonists led to a significant reduction in the risk for VTE among individuals with type 2 diabetes, compared with DPP-4 inhibitors, a recent indicated.

State of the Art Treatment in Myelofibrosis

Aaron Gerds, MD, MS discusses the state of the art treatment in myelofibrosis at the 2024 ASH Annual Meeting.

State of the Art Treatment in Polycythemia Vera

Aaron Gerds, MD, MS discusses the state of the art treatment in polycythemia vera at the 2024 ASH Annual Meeting.

The Aymara Gene: A Tale of High Altitude and Human Evolution

Josef T. Prchal, MD investigated the genetic basis underlying elevated hemoglobin in Andean natives, Aymara, by using granulocyte transcriptome data from both Aymara and Europeans from La Paz, Bolivia. They found their differentially expressed and spliced genes are associated with inflammatory and HIFs pathways.

Escape the Amyloid Maze: Unraveling Data and Care Strategies for AL Amyloidosis

Suzanne Lentzsch, MD, PhD explains a symposium presented at the 2024 ASH Annual Meeting on the clinical challenges and intricacies of care associated with the management of light chain amyloidosis.

Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial

Jennifer R. Brown, MD, PhD explains the interim analysis of the multicenter, open-label, randomized, phase 3 AMPLIFY trial presented at the 2024 ASH Annual Meeting.

High-Fiber NUTRIVENTION Study for Delaying Progression of Myeloma

Urvi A. Shah, MD discusses the NUTRIVENTION study, the current result from the trial, how it may delay progression of myeloma, and the importance of having a high fiber diet presented at the 2024 ASH Annual Meeting.

Guiding Our Patient's Path: Managing First Relapse in Diffuse Large B-Cell Lymphoma Outside of CAR-Ts

Gareth Gregory, MBBS, PhD on the options for treatment of diffuse large B-cell lymphoma, which have expanded in recent years, particularly with the emergence of bispecific antibodies.

Blinatumomab in Combination With Chemotherapy May Improve Survival in Pediatric Patients Newly Diagnosed With B-Cell Precursor ALL

Sumit Gupta, MD, PhD discusses results from the phase 3 Children’s Oncology Group Study AALL1731 presented at the 2024 ASH Annual Meeting. The study showed that adding blinatumomab to chemotherapy improved 3-year disease-free survival rates in newly diagnosed, standard risk pediatric B-cell acute lymphoblastic leukemia.

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant (MAIA)

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Best of ASH

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Multicenter Microbiota Analysis Indicates That Pre-HCT Microbiota Injury Is Prevalent across Geography and Predicts Poor Overall Survival

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)